Zobrazeno 1 - 10
of 48
pro vyhledávání: '"M. Brigid Bradley"'
Autor:
Madhav V. Dhodapkar, Philippe Armand, Alexander M. Lesokhin, Stephen M. Ansell, Martin Gutierrez, Emma C. Scott, Stephen J. Schuster, Adam D. Cohen, Scott J. Rodig, Margaret A. Shipp, Joseph F. Grosso, David Avigan, Michael Millenson, John M. Timmerman, Daniel Lebovic, Lili Zhu, Azra H. Ligon, Bjoern Chapuy, Ivan Borrello, Deepika Cattry, Ahmad Halwani, Gordon J. Freeman, M. Brigid Bradley Garelik
Publikováno v:
Journal of Clinical Oncology. 34:2698-2704
Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L
Autor:
Juan Luis Steegmann, Neil P. Shah, M. Brigid Bradley-Garelik, Carolina Pavlovsky, Mark Wildgust, Andreas Hochhaus, Dong-Wook Kim, Elias J. Jabbour, Hesham Mohamed, Concepción Boqué, Hagop M. Kantarjian, Michele Baccarani, Jorge E. Cortes, Jiri Mayer, Charles Chuah, Giuseppe Saglio
Publikováno v:
Blood. 123:494-500
This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 DASatinib versus Imatinib Study In treatment-Naive CML patients trial wi
Autor:
Juan Julio Kassack Ipiña, Mohan B. Agarwal, Michele Baccarani, Tadeusz Robak, M. Brigid Bradley-Garelik, Maria Soledad Undurraga, Jianxiang Wang, Neil P. Shah, Christian Junghanss, Franck E. Nicolini, Jorge Milone, Michinori Ogura, Andreas Hochhaus, Edo Vellenga, Dong-Wook Kim, Hagop M. Kantarjian, Jorge E. Cortes, Carolina Pavlovsky, Chao Zhu, Jan Van Droogenbroeck
Publikováno v:
Blood, 119(5), 1123-1129. AMER SOC HEMATOLOGY
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 DASISION trial, patients with newly diagnosed chronic-phase (CP) CML we
Autor:
Zhixiang Shen, Jiri Mayer, Sandip Shah, M. Brigid Bradley-Garelik, Charles Chuah, Andreas Hochhaus, Neil P. Shah, Eric Bleickardt, Michele Baccarani, Concepción Boqué, Ricardo Pasquini, Hagop M. Kantarjian, Ted Szatrowski, Jorge E. Cortes, David Shapiro, Hirohisa Nakamae, Beatriz Moiraghi, Manuel Ayala, Chao Zhu, Françoise Huguet
Publikováno v:
New England Journal of Medicine. 362:2260-2270
Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after fa
Autor:
Hervé Dombret, Chao Zhu, Tamas Masszi, Andreas Hochhaus, Frédéric Maloisel, Yeow Tee Goh, Jorge E. Cortes, Philipp Erben, M. Brigid Bradley-Garelik, Giuseppe Saglio, Ronald Paquette, Ricardo Pasquini
Publikováno v:
Cancer. 116:3852-3861
Patients with chronic myeloid leukemia (CML) who progress from the chronic phase (CML-CP) to the blast phase (CML-BP) have a poor prognosis.1 In these patients, conventional chemotherapy regimens are of limited value, and 2-year survival rates after
Autor:
Prakash Satwani, L.A. Baxter-Lowe, Diane George, B. Tallamy, Monica Bhatia, James Garvin, Michal J. Figurski, Zhezhen Jin, M. Brigid Bradley, Janet Ayello, O. Militano, Erin Morris, Virginia Moore, Leslie M. Shaw, Mitchell S. Cairo, Carmella van deVen
Publikováno v:
Biology of Blood and Marrow Transplantation. 16(3):333-343
Acute graft-versus-host disease (aGVHD) still remains a major limiting factor following allogeneic stem cell transplantation (AlloSCT) in pediatric recipients. Mycophenolate mofetil (MMF), an uncompetitive selective inhibitor of inosine monophosphate
Autor:
Mitchell S. Cairo, D. George, Carmella van de Ven, Jason Freedman, Bradford Tallamy, James Garvin, Jon Guerra, Erin Morris, Zhezhen Jin, Joseph Schwartz, Leah Baldinger, Judith S. Jacobson, Monica Bhatia, Prakash Satwani, M. Brigid Bradley
Publikováno v:
Biology of Blood and Marrow Transplantation. 15(12):1587-1595
Reductions in the duration and nadir of neutropenia have translated into a significant decrease in bacteremia in adult recipients of allogeneic stem cell transplantation (allo-SCT) with reduced-intensity conditioning (RIC) during the first 30 days af
Autor:
Yeow-Tee Goh, M. Brigid Bradley-Garelik, Jaydip Mukhopadhyay, Saengsuree Jootar, Wan-Seok Kim, Hui-Hua Hsiao, Tapan Saikia, Dong-Wook Kim, Amit Roy, Shruti Agrawal, David Dai, Dongho Kim, Priscilla B. Caguioa
Publikováno v:
International Journal of Hematology. 89:664-672
Resistance and intolerance to imatinib are of particular clinical relevance to Asian patients because of their lower body surface area. Dasatinib is 325-fold more potent than imatinib in inhibiting BCR-ABL in vitro and is indicated for the treatment
Autor:
Carmella van de Ven, Prakash Satwani, Erin Morris, Monica Bhatia, M. Brigid Bradley, Mitchell S. Cairo
Publikováno v:
Pediatric Blood & Cancer. 50:1-8
Allogeneic hematopoietic stem cell transplant (AlloSCT) from related or unrelated histocompatible donors has been well established as potentially curative therapy for children and adolescents with selected malignant and non-malignant diseases. In the
Publikováno v:
Experimental Hematology. 35:1753-1765
Stem cells have been isolated from human embryos, fetal tissue, umbilical cord blood (UCB), and also from "adult" sources. Adult stem cells are found in many tissues of the body and are capable of maintaining, generating, and replacing terminally dif